Based on the crucial role played by androgens and AR, hormonal therapy is one type of treatment available for prostate cancer [3,4], and the second-generation antiandrogen enzalutamide has been approved for castration-resistant prostate cancer. This evidence concerns the gene AR and prostate carcinoma.